Related Experiment Videos
Bradycardia during therapy for multiple myeloma with thalidomide
Ibrahim Elias Fahdi1, Venkat Gaddam, Jorge F Saucedo
1Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
The American Journal of Cardiology
|April 15, 2004
Summary
Thalidomide use in patients was associated with a higher incidence of bradycardia (slow heart rate). Reducing the thalidomide dose effectively managed these cardiac symptoms in most cases.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thalidomide is a medication with known cardiac side effects.
- Bradycardia, a slow heart rate, is a potential adverse event associated with drug therapies.
Purpose of the Study:
- To investigate the incidence of bradycardia in patients treated with thalidomide.
- To assess the impact of thalidomide dosage on the development of bradycardia.
Main Methods:
- Retrospective analysis of medical records.
- Comparison between a thalidomide group (96 patients) and a control group (104 patients).
- Monitoring of heart rate and occurrence of symptomatic bradycardia during follow-up.
Main Results:
- 53% of thalidomide patients experienced heart rates below 60 beats/min.
- 19% of thalidomide patients developed symptomatic bradycardia.
- Dose reduction of thalidomide led to symptom alleviation in the majority of affected patients.
Conclusions:
- Thalidomide treatment is linked to an increased risk of bradycardia.
- Symptomatic bradycardia in thalidomide users can often be managed by dose reduction.
- Close cardiac monitoring is recommended for patients on thalidomide therapy.